Accendra Health launches exchange offer for 4.5%/6.625% notes; new 9%/9.75% secured notes

ACCENDRA HEALTH INC/VA/

Offer to exchange $478.7M of 4.500% 2029 notes and $552.2M of 6.625% 2030 notes for secured notes.
New 9.000% First Lien Notes due 2032 and 9.750% Second Lien Notes due 2033; $326.25M new money issuance.
Backstop parties commit to buy up to $261M plus $65.25M of First Lien Notes; 3.5% cash premium.
Consent solicitations seek to eliminate substantially all affirmative/negative covenants and certain defaults.
Offers expire June 22, 2026; early exchange deadline June 9, 2026; withdrawal deadline same as early exchange.

item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-236869
form_type: 8-K
ticker: ACH
cik: 0000075252
company_name: ACCENDRA HEALTH INC/VA/
filed_at: 2026-05-22T20:08:11+00:00
discovered_at: 2026-05-22T20:09:00.470662+00:00
generated_at: 2026-05-22T20:12:41.064518+00:00
sec_items: ["7.01", "9.01"]
event_type: debt
sentiment: negative
materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-236869
json_url: https://secwatch.observer/filing/0001193125-26-236869.json
markdown_url: https://secwatch.observer/filing/0001193125-26-236869.md
text_url: https://secwatch.observer/filing/0001193125-26-236869.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/75252/000119312526236869/0001193125-26-236869-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/75252/000119312526236869/d28678d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-236869

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.